Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866707 · ClinicalTrials.gov registry record
Epigenetic and Metabolomic Changes in Childhood Cancer Survivors
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 7
- Enrollment target
NCT03866707 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 7 participants.
The verdict
NCT03866707 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.
Interventions
- OTHER One-time blood draw
- OTHER Evaluation of CpG methylation
- OTHER Metabolomic analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2020-05-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866707
The ClinicalTrials.gov registry entry for NCT03866707 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which One-time blood draw is the first listed.
NCT03866707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866707 about?
NCT03866707 is a clinical study titled "Epigenetic and Metabolomic Changes in Childhood Cancer Survivors". The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.
What is the current status of trial NCT03866707?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2019-02-25. Estimated completion is 2020-05-16.
What interventions are being tested in trial NCT03866707?
The interventions under investigation include: One-time blood draw (OTHER), Evaluation of CpG methylation (OTHER), Metabolomic analysis (OTHER).
Who is sponsoring clinical trial NCT03866707?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.